最新的10Q里面提到：In connection with our process of exploring commercialization options for Symjepi in the U.S. market after the FDA approval in June 2017, we retained an investment bank to assist us. We determined to engage in a process with the goal of maximizing the value of the asset. The process has been ongoing and as of the date of this Report on Form 10-Q, we are in active discussions with several potential partners regarding commercialization of the product. We have begun building inventory in anticipation of a commercial launch. 
